Challenges in diagnosing coexisting ocular myasthenia gravis and thyroid eye disease
Benjamin Claytor MD
Neuromuscular Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA
Search for more papers by this authorCorresponding Author
Yuebing Li MD, PhD
Neuromuscular Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA
Correspondence
Yuebing Li, Neuromuscular Center, Neurological Institute, Cleveland Clinic, 9500 Euclid Avenue, Desk S90, Cleveland, Ohio 44195.
Email: [email protected]
Search for more papers by this authorBenjamin Claytor MD
Neuromuscular Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA
Search for more papers by this authorCorresponding Author
Yuebing Li MD, PhD
Neuromuscular Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA
Correspondence
Yuebing Li, Neuromuscular Center, Neurological Institute, Cleveland Clinic, 9500 Euclid Avenue, Desk S90, Cleveland, Ohio 44195.
Email: [email protected]
Search for more papers by this authorAbstract
Ocular myasthenia gravis (OMG) and thyroid eye disease are two autoimmune conditions that have several overlapping clinical features, and these coexist with a small but not insignificant frequency. Segregating these diagnoses is typically straightforward, but, when the two diseases co-occur in the same individual, making a diagnosis of OMG can be very challenging. In this review we address what is known about the coexistence of OMG and thyroid eye disease and we highlight the clinical features that are suggestive of overlapping conditions. We also describe the major testing approaches used in the diagnosis of these two entities, with special emphasis on the potential shortcomings of individual tests in patients with overlapping disease. In patients with thyroid eye disease, securing a diagnosis of OMG may not be possible on the basis of a single positive test. A multimodal approach using clinical, serologic, imaging, and electrodiagnostic data, is typically required.
CONFLICT OF INTEREST
Y.L. has served as a consultant for Argenx. B.C. declares no conflicts of interest.
REFERENCES
- 1Mao ZF, Yang LX, Mo XA, et al. Frequency of autoimmune diseases in myasthenia gravis: a systematic review. Int J Neurosci. 2011; 121: 121-129.
- 2Nacu A, Andersen JB, Lisnic V, Owe JF, Gilhus NE. Complicating autoimmune diseases in myasthenia gravis: a review. Autoimmunity. 2015; 48: 362-368.
- 3Boelaert K, Newby PR, Simmonds MJ, et al. Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease. Am J Med. 2010; 123: 183.e1-183.e9.
- 4Ohno M, Hamada N, Yamakawa J, Noh J, Morii H, Ito K. Myasthenia gravis associated with Graves' disease in Japan. Jpn J Med. 1987; 26: 2-6.
- 5Phillips LH. The epidemiology of myasthenia gravis. Ann NY Acad Sci. 2003; 998: 407-412.
- 6Lin YP, Iqbal U, Nguyen PA, et al. The concomitant association of thyroid disorders and myasthenia gravis. Transl Neurosci. 2017; 8: 27-30.
- 7Yang HW, Wang YX, Bao J, Wang SH, Lei P, Sun ZL. Correlation of and gene polymorphisms with ocular myasthenia gravis combined with thyroid-associated ophthalmopathy. Biosci Rep. 2017; 37(2): BSR220160440.
- 8Batocchi AP, Evoli A, Majolini L, et al. Ocular palsies in the absence of other neurological or ocular symptoms: analysis of 105 cases. J Neurol. 1997; 244: 639-645.
- 9Castelluccia A, Nociti V, Frisullo G, Batocchi AP. A prospective study on 132 cases of ocular palsy. Eur Neurol. 2013; 70: 10-15.
- 10Engel AG. Thyroid function and myasthenia gravis. Arch Neurol. 1961; 4: 663-674.
- 11Weetman AP. Graves' disease. N Engl J Med. 2000; 343: 1236-1248.
- 12Villadolid MC, Yokoyama N, Izumi M, et al. Untreated Graves' disease patients without clinical ophthalmopathy demonstrate a high frequency of extraocular muscle (EOM) enlargement by magnetic resonance. J Clin Endocrinol Metab. 1995; 80: 2830-2833.
- 13Bartley GB, Fatourechi V, Kadrmas EF, et al. Clinical features of Graves' ophthalmopathy in an incidence cohort. Am J Ophthalmol. 1996; 121: 284-290.
- 14Bojikian KD, Francis CE. Thyroid eye disease and myasthenia gravis. Int Ophthalmol Clin. 2019; 59: 113-124.
- 15Strianese D, Piscopo R, Elefante A, et al. Unilateral proptosis in thyroid eye disease with subsequent contralateral involvement: retrospective follow-up study. BMC Ophthalmol. 2013; 13: 21.
- 16Leonard TJ, Graham EM, Stanford MR, Sanders MD. Graves' disease presenting with bilateral acute painful proptosis, ptosis, ophthalmoplegia, and visual loss. Lancet. 1984; 2: 431-433.
- 17Lohman L, Burns JA, Penland WR, Cahill KV. Unilateral eyelid retraction secondary to contralateral ptosis in dysthyroid ophthalmopathy. J Clin Neuroophthalmol. 1984; 4: 163-166.
- 18Nicolle MW. Pseudo-myasthenia gravis and thymic hyperplasia in Graves' disease. Can J Neurol Sci. 1999; 26: 201-203.
- 19Uldry PA, Regli F, Scazziga BR, Naegeli C. Palpebral asymmetry and hyperthyroidism. Two cases in connection with Graves' disease. J Neurol. 1986; 233: 126-127.
- 20Spector RH, Carlisle JA. Minimal thyroid ophthalmopathy. Neurology. 1987; 37: 1803-1808.
- 21Perros P, Crombie AL, Kendall-taylor P. Natural history of thyroid associated ophthalmopathy. Clin Endocrinol (Oxf). 1995; 42: 45-50.
- 22Douglas RS, Kahaly GJ, Patel A, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020; 382: 341-352.
- 23Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve. 2008; 37: 141-149.
- 24Mazzoli M, Ariatti A, Valzania F, et al. Factors affecting outcome in ocular myasthenia gravis. Int J Neurosci. 2018; 128: 15-24.
- 25Nagia L, Lemos J, Abusamra K, Cornblath WT, Eggenberger ER. Prognosis of ocular myasthenia gravis: retrospective multicenter analysis. Ophthalmology. 2015; 122: 1517-1521.
- 26Peeler CE, De lott LB, Nagia L, Lemos J, Eggenberger ER, Cornblath WT. Clinical utility of acetylcholine receptor antibody testing in ocular myasthenia gravis. JAMA Neurol. 2015; 72: 1170-1174.
- 27Morren J, Li Y. Maintenance immunosuppression in myasthenia gravis an update. J Neurol Sci. 2020; 410:116648.
- 28Weinberg DA, Lesser RL, Vollmer TL. Ocular myasthenia: a protean disorder. Surv Ophthalmol. 1994; 39: 169-210.
- 29Singman EL, Matta NS, Silbert DI. Use of the Cogan lid twitch to identify myasthenia gravis. J Neuroophthalmol. 2011; 31: 239-240.
- 30Bixenman WW, Buchsbaum HW. Multiple sclerosis, euthyroid restrictive Grave's ophthalmopathy, and myasthenia gravis. A case report. Graefes Arch Clin Exp Ophthalmol. 1988; 226: 168-171.
- 31Spoor TC, Martinez AJ, Kennerdell JS, Mark LE. Dysthyroid and myasthenic myopathy of the medial rectus: a clinical pathologic report. Neurology. 1980; 30: 939-944.
- 32Czernobilsky H, Ziegler R. Graves' ophthalmopathy, ocular myasthenia gravis and Hashimoto's thyroiditis. Isr J Med Sci. 1985; 21: 377-380.
- 33Raef H, Ladinsky M, Arem R. Concomitant euthyroid Graves' ophthalmopathy and isolated ocular myasthenia gravis. Postgrad Med J. 1990; 66: 849-852.
- 34Vargas ME, Warren FA, Kupersmith MJ. Exotropia as a sign of myasthenia gravis in dysthyroid ophthalmopathy. Br J Ophthalmol. 1993; 77: 822-823.
- 35Tanwani LK, Lohano V, Ewart R, Broadstone VL, Mokshagundam SP. Myasthenia gravis in conjunction with Graves' disease: a diagnostic challenge. Endocr Pract. 2001; 7: 275-278.
- 36Yaman A, Yaman H. Ocular myasthenia gravis coincident with thyroid ophthalmopathy. Neurol India. 2003; 51: 100-101.
- 37Kusuhara T, Nakajima M, Imamura A. Ocular myasthenia gravis associated with euthyroid ophthalmopathy. Muscle Nerve. 2003; 28: 764-766.
- 38Zouvelou V, Potagas C, Karandreas N, et al. Concurrent presentation of ocular myasthenia and euthyroid graves ophthalmopathy: a diagnostic challenge. J Clin Neurosci. 2008; 15: 719-720.
- 39Polymeris A, Karoutsou E, Doumouchtsis K. Seronegative myasthenia gravis and Graves' disease. Is there a link? Exp Clin Endocrinol Diabetes. 2012; 120: 254-256.
- 40Kang H, Takahashi Y, Iwaki M, Asamura S, Kakizaki H. Upper eyelid retraction disclosed after edrophonium chloride administration in a patient with Graves' orbitopathy and myasthenia gravis. Clin Ophthalmol. 2012; 6: 807-810.
- 41Selvan C, Dutta D, Maisnam I, et al. Thyroid associated orbitopathy with ocular myasthenia in primary hypothyroidism: keep those eyes open. Indian J Endocrinol Metab. 2013; 17(Suppl 3): S657-S659.
- 42Biswas K, Sharma M, Dutta D, Barman N. Ocular myasthenia with thyroid associated ophthalmopathy in subclinical Graves' disease: diagnostic challenge and treatment outcomes. Thyroid Res Pract. 2014; 11: 73-75.
10.4103/0973-0354.129734 Google Scholar
- 43Canepa C, Venu M. Progressive bilateral ophthalmoparesis—a case of simultaneous autoimmunity: balancing Graves' ophthalmoparesis and ocular myasthenia. BMJ Case Rep. 2016; 2016:bcr2015213395.
- 44Sehgal S, Rebello R, Wolmarans L, Elston M. Hickam's dictum: myasthenia gravis presenting concurrently with graves' disease. BMJ Case Rep. 2017; 2017:bcr2017220153.
- 45An R, Li Y, Yang B, Wang H, Xu Y. Rare co-occurrence of ocular myasthenia gravis and thyroid-associated orbitopathy (ophthalmopathy) in an individual with hypothyroidism. Front Endocrinol (Lausanne). 2018; 9: 801.
- 46Ma R, Cheng Y, Gan L, Zhou X, Qian J. Histopathologic study of extraocular muscles in thyroid-associated ophthalmopathy coexisting with ocular myasthenia gravis: a case report. BMC Ophthalmol. 2020; 20: 166.
- 47Cruz AA, Akaishi PM, Vargas MA, De Paula SA. Association between thyroid autoimmune dysfunction and non-thyroid autoimmune diseases. Ophthalmic Plast Reconstr Surg. 2007; 23: 104-108.
- 48Kashkouli MB, Jam S, Sabzvari D, et al. Thyroid-associated ophthalmopathy in Iranian patients. Acta Med Iran. 2011; 49: 612-618.
- 49Chen YL, Yeh JH, Chiu HC. Clinical features of myasthenia gravis patients with autoimmune thyroid disease in Taiwan. Acta Neurol Scand. 2013; 127: 170-174.
- 50Marinò M, Barbesino G, Pinchera A, et al. Increased frequency of euthyroid ophthalmopathy in patients with Graves' disease associated with myasthenia gravis. Thyroid. 2000; 10: 799-802.
- 51Guptill JT, Sanders DB, Evoli A. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve. 2011; 44: 36-40.
- 52Marinó M, Ricciardi R, Pinchera A, et al. Mild clinical expression of myasthenia gravis associated with autoimmune thyroid diseases. J Clin Endocrinol Metab. 1997; 82: 438-443.
- 53de Meel RHP, Raadsheer WF, van Zwet EW, Tannemaat MR, Verschuuren JJGM. Ocular weakness in myasthenia gravis: changes in affected muscles are a distinct clinical feature. J Neuromuscul Dis. 2019; 6: 369-376.
- 54Ragge NK, Hoyt WF. Midbrain myasthenia: fatigable ptosis, 'lid twitch' sign, and ophthalmoparesis from a dorsal midbrain glioma. Neurology. 1992; 42: 917-919.
- 55Tsuda E, Imai T, Matsumura A, et al. Thyrotoxic myopathy mimicking myasthenic syndrome associated with thymic hyperplasia. Intern Med. 2008; 47: 445-447.
- 56Chiu WY, Yang CC, Huang IC, Huang TS. Dysphagia as a manifestation of thyrotoxicosis: report of three cases and literature review. Dysphagia. 2004; 19: 120-124.
- 57Kahaly GJ. Imaging in thyroid-associated orbitopathy. Eur J Endocrinol. 2001; 145: 107-118.
- 58Weinberg DH, Rizzo JFIII, Hayes MT, Kneeland MD, Kelly JJ Jr. Ocular myasthenia gravis: predictive value of single-fiber electromyography. Muscle Nerve. 1999; 22: 1222-1227.
10.1002/(SICI)1097-4598(199909)22:9<1222::AID-MUS8>3.0.CO;2-R CAS PubMed Web of Science® Google Scholar
- 59Farrugia ME, Robson MD, Clover L, et al. MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis. Brain. 2006; 129: 1481-1492.
- 60Okamoto K, Ito J, Tokiguchi S, Furusawa T. Atrophy of bilateral extraocular muscles. CT and clinical features of seven patients. J Neuroophthalmol. 1996; 16: 286-288.
- 61Mao ZF, Mo XA, Qin C, Lai YR, Hackett ML. Incidence of thymoma in myasthenia gravis: a systematic review. J Clin Neurol. 2012; 8: 161-169.
- 62Huang X, Liu WB, Men LN, et al. Clinical features of myasthenia gravis in southern China: a retrospective review of 2,154 cases over 22 years. Neurol Sci. 2013; 34: 911-917.
- 63Karni A, Asmail A, Drory VE, Kolb H, Kesler A. Characterization of patients with ocular myasthenia gravis—a case series. eNeurol Sci. 2016; 4: 30-33.
- 64Haider U, Richards P, Gianoukakis AG. Thymic hyperplasia associated with Graves' disease: pathophysiology and proposed management algorithm. Thyroid. 2017; 27: 994-1000.
- 65van Herle AJ, Chopra IJ. Thymic hyperplasia in Graves' disease. J Clin Endocrinol Metab. 1971; 32: 140-146.
- 66Murakami M, Hosoi Y, Negishi T, et al. Thymic hyperplasia in patients with Graves' disease. Identification of thyrotropin receptors in human thymus. J Clin Invest. 1996; 98: 2228-2234.
- 67Marx A, Pfister F, Schalke B, Nix W, Ströbel P. Thymus pathology observed in the MGTX trial. Ann NY Acad Sci. 2012; 1275: 92-100.
- 68Puvanendran K, Cheah JS, Naganathan N, Yeo PP, Wong PK. Neuromuscular transmission in thyrotoxicosis. J Neurol Sci. 1979; 43: 47-57.
- 69Padua L, Stalberg E, Lomonaco M, Evoli A, Batocchi A, Tonali P. SFEMG in ocular myasthenia gravis diagnosis. Clin Neurophysiol. 2000; 111: 1203-1207.
- 70Padua L, Caliandro P, Di Iasi G, Pazzaglia C, Ciaraffa F, Evoli A. Reliability of SFEMG in diagnosing myasthenia gravis: sensitivity and specificity calculated on 100 prospective cases. Clin Neurophysiol. 2014; 125: 1270-1273.
- 71Lo YL, Najjar RP, Teo KY, Tow SL, Loo JL, Milea D. A reappraisal of diagnostic tests for myasthenia gravis in a large Asian cohort. J Neurol Sci. 2017; 376: 153-158.
- 72Krendel DA, Sanders DB, Massey JM. Single fiber electromyography in chronic progressive external ophthalmoplegia. Muscle Nerve. 1987; 10: 299-302.
- 73Oh SJ. The single-fiber EMG in chronic demyelinating neuropathy. Muscle Nerve. 1989; 12: 371-377.
- 74Liu M, Cui L, Guan Y, Li B, Du H. Single-fiber electromyography in amyotrophic lateral sclerosis and cervical spondylosis. Muscle Nerve. 2013; 48: 137-139.
- 75Roos JCP, Paulpandian V, Murthy R. Serial TSH-receptor antibody levels to guide the management of thyroid eye disease: the impact of smoking, immunosuppression, radio-iodine and thyroidectomy. Eye (Lond). 2019; 33: 212-217.
- 76Klein R, Marx A, Ströbel P, Schalke B, Nix W, Willcox N. Autoimmune associations and autoantibody screening show focused recognition in patient subgroups with generalized myasthenia gravis. Hum Immunol. 2013; 74: 1184-1193.
- 77Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and nutrition examination survey (NHANES III). J Clin Endocrinol Metab. 2002; 87: 489-499.
- 78Garlepp MJ, Dawkins RL, Christiansen FT, et al. Autoimmunity in ocular and generalised myasthenia gravis. J Neuroimmunol. 1981; 1: 325-232.
- 79Benatar M. A systematic review of diagnostic studies in myasthenia gravis. Neuromuscul Disord. 2006; 16: 459-467.
- 80Jacobson DM. Acetylcholine receptor antibodies in patients with Graves' ophthalmopathy. J Neuroophthalmol. 1995; 15: 166-170.
- 81Robb SA, Vincent A, Mcgregor MA, Mcgregor AM, Newsom-Davis JM. Acetylcholine receptor antibodies in the elderly and in Down's syndrome. J Neuroimmunol. 1985; 9: 139-146.
- 82Beekman R, Kuks JB, Oosterhuis HJ. Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients. J Neurol. 1997; 244: 112-118.
- 83Dirr LY, Donofrio PD, Patton JF, Troost BT. A false-positive edrophonium test in a patient with a brainstem glioma. Neurology. 1989; 39: 865-867.
- 84Chatzistefanou KI, Kouris T, Iliakis E, et al. The ice pack test in the differential diagnosis of myasthenic diplopia. Ophthalmology. 2009; 116: 2236-2243.
- 85Park JY, Yang HK, Hwang JM. Diagnostic value of repeated ice tests in the evaluation of ptosis in myasthenia gravis. PLoS One. 2017; 12:e0177078.